Caribou Biosciences, INC. (CRBU) — 10-Q Filings

All 10-Q filings from Caribou Biosciences, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Caribou Biosciences' Losses Widen Amid Impairment Charges — Nov 12, 2025 Risk: high
Caribou Biosciences, Inc. (CRBU) reported a net loss of $121.6 million for the nine months ended September 30, 2025, an increase from $113.6 million in the same
Caribou Biosciences' Losses Widen Amidst R&D Spend — Aug 12, 2025 Risk: high
Caribou Biosciences, Inc. reported a net loss of $49.2 million for the three months ended June 30, 2025, an increase from the $40.5 million net loss for the sam
Caribou Biosciences Q1 2025 10-Q Filing — May 8, 2025 Risk: medium
Caribou Biosciences, Inc. filed its quarterly report for the period ending March 31, 2025. The company, focused on biological products, reported its financial s
Caribou Biosciences Files Q3 2024 10-Q — Nov 6, 2024 Risk: medium
Caribou Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its operat
Caribou Biosciences 10-Q: Q2 2024 Financial Update — Aug 6, 2024 Risk: medium
Caribou Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance and business operations. The filing details
Caribou Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk: medium
Caribou Biosciences, Inc. (CRBU) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Caribou Biosciences reported financial results for the quarter end

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX